ABVC BioPharma, Inc.
Index- P/E- EPS (ttm)-0.51 Insider Own46.08% Shs Outstand25.05M Perf Week-15.10%
Market Cap59.45M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float16.34M Perf Month-21.80%
Income-12.80M PEG- EPS next Q- Inst Own1.50% Short Float0.47% Perf Quarter-17.13%
Sales0.40M P/S148.62 EPS this Y-3.20% Inst Trans- Short Ratio1.23 Perf Half Y-39.18%
Book/sh0.35 P/B5.94 EPS next Y- ROA-112.80% Target Price9.50 Perf Year-62.18%
Cash/sh0.21 P/C10.08 EPS next 5Y- ROE-239.40% 52W Range1.95 - 11.69 Perf YTD-38.64%
Dividend- P/FCF- EPS past 5Y-8.30% ROI-120.50% 52W High-82.21% Beta0.57
Dividend %- Quick Ratio2.60 Sales past 5Y- Gross Margin98.60% 52W Low6.67% ATR0.19
Employees28 Current Ratio2.60 Sales Q/Q300.00% Oper. Margin- RSI (14)38.50 Volatility9.76% 7.94%
OptionableNo Debt/Eq0.18 EPS Q/Q-115.60% Profit Margin- Rel Volume0.21 Prev Close2.09
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume63.03K Price2.08
Recom- SMA20-12.52% SMA50-15.52% SMA200-26.27% Volume13,402 Change-0.48%
May-16-22 05:46PM  
May-13-22 08:30AM  
May-12-22 09:00AM  
May-10-22 08:30AM  
May-05-22 08:30AM  
May-03-22 08:30AM  
Apr-28-22 08:30AM  
Apr-26-22 08:30AM  
Mar-31-22 04:18PM  
Mar-23-22 09:25AM  
Mar-08-22 06:15AM  
Feb-02-22 08:00AM  
Jan-05-22 08:30AM  
Dec-22-21 08:30AM  
Dec-15-21 08:30AM  
Dec-10-21 01:38PM  
Dec-09-21 08:30AM  
Nov-15-21 04:33PM  
Nov-11-21 09:00AM  
Nov-03-21 11:18AM  
Nov-02-21 06:18AM  
Nov-01-21 11:32AM  
Oct-27-21 08:30AM  
Oct-15-21 12:05PM  
Oct-12-21 08:30AM  
Sep-13-21 08:30AM  
Sep-01-21 03:54PM  
Aug-30-21 08:30AM  
Aug-26-21 08:30AM  
Aug-12-21 08:27AM  
Aug-06-21 08:30AM  
Aug-03-21 08:30AM  
Jun-09-21 10:20AM  
Jan-27-21 04:55AM  
Jan-06-21 09:00AM  
Nov-09-20 09:00AM  
Sep-09-20 09:00AM  
Aug-24-20 09:00AM  
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.